Eisai and Biogen presented findings from a Clarity AD substudy at the 19th CTAD conference on November 19, 2026. The post hoc analysis revealed that lecanemab slowed clinical decline by 41% on the CDR-SB scale in patients with α-synuclein co-pathology, outperforming the 27% reduction observed in the overall study population.
Post hoc Clarity AD CSF substudy data presented at CTAD on Nov 19, 2026 show lecanemab slowed decline by 41% on CDR-SB in α-Syn+ patients versus 27% in the overall population, supporting clinical benefit in a faster-declining subgroup. Biogen co-commercializes the product, so stronger evidence could support LEQEMBI uptake. The analysis is post hoc and exploratory, and no new approval or sales figures were given, limiting the effect.
- ▲ CTAD 2026 oral presentation on Nov 19, 2026 of Clarity AD CSF substudy findings
- ▲ α-Syn+ subgroup showing 41% reduction in decline on CDR-SB vs 27% in overall population
- ▼ Post hoc exploratory analysis, not a new registrational result
- ▼ No new revenue, guidance or regulatory milestone disclosed